Literature DB >> 3213614

Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate.

C W Löwik1, G van der Pluijm, L J van der Wee-Pals, H B van Treslong-De Groot, O L Bijvoet.   

Abstract

Osteoclast-devoid bone explants were cultured together with embryonic liver as a source of osteoclast precursors, but separated from each other by a filter. Cells migrated through the filter toward the calcified matrix and acquired the characteristics of mature, tartrate-resistant acid phosphatase-positive (TRAP+) osteoclasts upon contact with the bone explant. Migration and attachment could be visualized separately. Progressive reduction of filter pore size resulted in progressive reduction of resorption because the use of smaller pores made it increasingly difficult for cells to pass. Indeed, the use of 0.22-micron filters, through which no cells can pass, but which still allow full passage of medium, completely blocked the resorption. When migrating cells from fetal liver were arrested for 10 days by using a combination of filters with different pore sizes, the arrested cells showed a tendency to fuse just opposite the mineralized matrix. Furthermore, a great number of the arrested cells expressed the macrophage-specific cell-surface antigen F4/80 and showed acid phosphatase activity, but none of these cells were tartrate resistant. The acquisition of tartrate-resistant acid phosphatase activity upon contact with the bone explant and subsequent resorption of this explant could be prevented by exposure of the system to the bisphosphonate dimethyl-APD (Me2-APD), whereas migration of cells through the filter was not affected. We suggest that the bisphosphonate interferes with a matrix factor that is essential for the attachment and subsequent transformation of the osteoclast precursor into the mature phenotype.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3213614     DOI: 10.1002/jbmr.5650030210

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  45 in total

1.  Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro.

Authors:  G van der Pluijm; H Vloedgraven; E van Beek; L van der Wee-Pals; C Löwik; S Papapoulos
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

2.  Small interfering RNA knocks down the molecular target of alendronate, farnesyl pyrophosphate synthase, in osteoclast and osteoblast cultures.

Authors:  Yuwei Wang; Alexandra Panasiuk; David W Grainger
Journal:  Mol Pharm       Date:  2011-01-21       Impact factor: 4.939

3.  Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro.

Authors:  A Carano; S L Teitelbaum; J D Konsek; P H Schlesinger; H C Blair
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

4.  Effect of the cumulative dose of zoledronic acid on the pathogenesis of osteonecrosis of the jaws.

Authors:  Meral Günaldi; Cigdem Usul Afsar; Berna Bozkurt Duman; Ismail Oguz Kara; Ufuk Tatli; Berksoy Sahin
Journal:  Oncol Lett       Date:  2015-04-27       Impact factor: 2.967

5.  Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with bisphosphonates for bone metastases.

Authors:  Annalisa Bramati; Serena Girelli; Gabriella Farina; Maria Chiara Dazzani; Valter Torri; Anna Moretti; Sheila Piva; Mariastella Dimaiuta; Nicla La Verde
Journal:  J Bone Miner Metab       Date:  2014-02-20       Impact factor: 2.626

6.  Acid extrusion is induced by osteoclast attachment to bone. Inhibition by alendronate and calcitonin.

Authors:  Z Zimolo; G Wesolowski; G A Rodan
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

Review 7.  New bisphosphonates in osteoporosis.

Authors:  H Fleisch
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

8.  Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone.

Authors:  A M Flanagan; T J Chambers
Journal:  Calcif Tissue Int       Date:  1991-12       Impact factor: 4.333

Review 9.  Hypercalcaemia of malignancy.

Authors:  P J Kelly; J A Eisman
Journal:  Cancer Metastasis Rev       Date:  1989-06       Impact factor: 9.264

Review 10.  Bisphosphonates and the treatment of bone disease in the elderly.

Authors:  A Johansen; M Stone; F Rawlinson
Journal:  Drugs Aging       Date:  1996-02       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.